ANALGESICS – AUSTRALIA

Panadol’s continuing dominance proves a pain for competitors

roymorgansocial Leave a comment

Original article by Roy Morgan
Market Research Update – Page: Online : 6-Aug-19

New research from Roy Morgan shows that 12.4 million Australians aged 14+ (60.4%) purchased headache and pain relief products in an average four weeks in the year to March 2019, up from 12.1 million in 2016. Some 7.8 million Australians (38% of the population) purchase Panadol-brand pain relief products in an average four weeks, followed by Nurofen (21.8%) and supermarket brands (9.9%). The research also shows that over the past three years, the proportion of Australians who purchase Panadol has increased by 0.8% points, while Nurofen has decreased by 1.2% points. Meanwhile, 30.1% of Australians indicate that they buy pain relief products from chemists or pharmacies in an average six months, while supermarkets are the next preferred choice (26%).

CORPORATES
ROY MORGAN LIMITED

Nurofen range to be pulled over claims

roymorgansocial Leave a comment

Original article by Patrick Hatch
The Australian Financial Review – Page: 3 : 15-Dec-15

The Federal Court has ruled that Reckitt Benckiser misled consumers by claiming that its Nurofen painkillers are specially formulated to treat specific medical conditions. The Australian Competition & Consumer Commission took legal action after alleging that each Nurofen product contains the same active ingredient. Reckitt Benckiser has been given three months to withdraw the specific-pain products from sale, but it will be allowed to keep marketing them for 12 months provided the packaging indicates that the products can be used to treat other types of pain.

CORPORATES
RECKITT BENCKISER (AUSTRALIA) PTY LTD, FEDERAL COURT OF AUSTRALIA, AUSTRALIAN COMPETITION AND CONSUMER COMMISSION, AUSTRALIA. THERAPEUTIC GOODS ADMINISTRATION